Tau aggregates start to form in the brain 10–15 years before the manifestation of any clinical symptoms, thus presenting an appealing possibility to diagnose and monitor tauopathies by using tau aggregates as an early biomarker. The gene discussed is MAPT; the disease is tauopathy.